Can immunotherapy for melanoma cause significant lymph node swelling?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Immunotherapy Cause Significant Lymph Node Swelling in Melanoma?

Yes, immunotherapy for melanoma can cause significant lymph node swelling, specifically a phenomenon called "sarcoid-like lymphadenopathy" or granulomatous lymphadenitis, which appears in approximately 10% of patients and paradoxically may indicate treatment response rather than disease progression.

Understanding This Immune-Related Adverse Event

Lymph node swelling during immunotherapy represents a recognized immune-related adverse event that requires careful clinical interpretation:

Key Clinical Patterns

The granulomatous reaction typically manifests as:

  • Mediastinal and hilar lymphadenopathy appearing approximately 6 months after immunotherapy initiation 1
  • "Sarcoid-like lymphadenopathy" visible on PET/CT imaging 2
  • Can mimic disease recurrence or progression both clinically and radiographically 1

Critical Diagnostic Distinction

This is a crucial clinical pitfall: The lymph node enlargement may appear identical to metastatic disease on imaging, but biopsy reveals benign granulomatous inflammation rather than tumor cells 1. All patients who developed this sarcoid-like pattern in one study showed disease control, suggesting this may be a favorable prognostic sign 2.

Clinical Management Algorithm

When encountering new lymphadenopathy during immunotherapy:

  1. Consider timing: Typically occurs around 6 months into treatment 1
  2. Evaluate disease response: If other disease sites show favorable response, suspect immune-related lymphadenopathy rather than progression 1
  3. Obtain tissue diagnosis: Biopsy is essential to differentiate granulomatous reaction from metastatic disease 1
  4. Continue immunotherapy: If biopsy confirms granulomatous reaction, immunotherapy should be continued as this represents an immune-related adverse event, not treatment failure 1

Prognostic Implications

The presence of this lymphadenopathy may actually be favorable: In the study evaluating ipilimumab-treated patients, all patients (100%) who developed sarcoid-like lymphadenopathy achieved disease control, with some achieving complete or near-complete responses 2, 1. This suggests the lymph node changes reflect robust immune activation rather than treatment failure.

Important Caveats

  • This phenomenon is distinct from baseline lymph node involvement by melanoma
  • Not all lymph node enlargement during immunotherapy is benign—tissue diagnosis is mandatory to avoid premature treatment discontinuation
  • The 10% incidence means most patients will not develop this finding 2
  • Awareness of this adverse event is crucial to prevent inappropriate treatment cessation in responding patients 1

The ESMO guidelines on immunotherapy toxicity management 3 emphasize that immune-related adverse events can affect multiple organ systems, and lymphoid tissue changes represent one manifestation of immune activation during checkpoint inhibitor therapy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.